SCHEMBL7605555

SCHEMBL7605555

CCN(CC)C1=NN(c2ccc(OC)cc2)C(=O)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
APP P05067 1/20 0.42
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
GAA P10253 3/20 0.40
MAPK1 P28482 1/20 0.40
GFER P55789 1/20 0.40
ELANE P08246 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
HPGD P15428 2/20 0.38
MGLL Q99685 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734971 0.85 KMT2A (0.40) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL7604775 0.84 APP (0.44) MAPTSMN1; SMN2ALDH1A1LMNAAPP
SCHEMBL7612605 0.82 MEN1 (0.46) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL7616760 0.82 KMT2A (0.44) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL6730744 0.75 KMT2A (0.48) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL6727775 0.75 APP (0.51) MAPTALDH1A1LMNAL3MBTL1APP
SCHEMBL6733346 0.75 APP (0.48) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL6738592 0.73 APP (0.52) MAPTALDH1A1KDM4ELMNAAPP
SCHEMBL7612002 0.71 PDE4D (0.50) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL6933171 0.71 ELANE (0.43) MAPTSMN1; SMN2ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020031536-A1 Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof L'OREAL SA 2002-03-14 US disclosed
US-6322775-B1 FOR COLORING THE SKIN AND/OR THE HAIR; SIDE EFFECTS REDUCTION; STABILITY L'OREAL S.A. (FR) 2001-11-27 US disclosed
EP-0888306-B1 COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF OREAL (FR) 2001-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020031536-A1 Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof PPARD, PLIN5, PDK4 MAPT 3025/4885SMN1; SMN2 4880/4885ALDH1A1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.